Maggino L, et al. - Researchers prospectively studied 680 patients, including 267 with borderline resectable and 413 with locally advanced pancreatic ductal adenocarcinoma receiving primary chemotherapy, for their treatment compliance, conversion to surgery, and survival outcomes. The cohort had chemotherapy receipt and completion rates of 92.9% and 71.6%, respectively. Surgical resection was performed in 24% of patients with borderline resectable disease and 9% of patients with locally advanced disease. The whole cohort had median survival of 12.8 months and in patients who underwent surgical resection it was in excess of 35 months. No correlation of any of the pretreatment and posttreatment factors with survival after pancreatectomy was observed. Completion of chemotherapy, receipt of complementary radiation therapy, and resection were independently associated with survival.